Issues related to development of antiepileptogenic therapies

Area of Science:

• Neurology
• Epilepsy Research
• Translational Medicine

Background:

• Preclinical studies show promise for antiepileptogenic therapies, but none have reached clinical application.
• Failures in translating preclinical epilepsy data to clinics mirror issues seen in stroke, Alzheimer's, and ALS research.
• Problems in preclinical study design are a likely cause for the lack of clinical translation.

Purpose of the Study:

• To address challenges in developing antiepileptogenic (AEG) therapies.
• To provide recommendations for designing preclinical AEG monotherapy trials in adult animals.
• To guide future actions for advancing preclinical AEG testing.

Main Methods:

• The International League Against Epilepsy (ILAE) and American Epilepsy Society (AES) convened a working group.
• Discussions focused on issues moving from proof-of-concept to preclinical and clinical AEG trials.
• Recommendations cover study design, animal/model selection, treatment administration, outcomes, statistics, and reporting.

Main Results:

• Identified critical issues in preclinical study design for antiepileptogenesis.
• Provided specific recommendations for conducting preclinical AEG monotherapy trials.
• Outlined strategies to bridge the gap between preclinical findings and clinical application.

Conclusions:

• Standardized and rigorous preclinical trial design is crucial for successful translation of antiepileptogenic therapies.
• Addressing methodological challenges in preclinical research will accelerate the development of new epilepsy treatments.
• Collaboration and clear guidelines are needed to advance AEG therapy development.